Redbud Labs, Inc.
Publicly observedDurham, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Durham | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Redbud Labs, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | KJGXVMFV9U14 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant22 Jul 2026Publicly observed
NIH SBIR/STTR award: Redbud NA1 transfer to manufacturing
USD 956,224.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant16 Sept 2022Publicly observed
NIH SBIR/STTR award: Improving extraction success of FFPE samples with automated and reliable microfluidic sample preparation
USD 50,000.00 · National Institute of General Medical Sciences · Source: NIH RePORTER (opens in a new tab)
- Grant16 Sept 2022Publicly observed
NIH SBIR/STTR award: Improving extraction success of FFPE samples with automated and reliable microfluidic sample preparation
USD 1,261,092.00 · National Institute of General Medical Sciences · Source: NIH RePORTER (opens in a new tab)
- Grant17 Feb 2022Publicly observed
NIH SBIR/STTR award: System for unitary automation of library preparation
USD 48,000.00 · National Institute of General Medical Sciences · Source: NIH RePORTER (opens in a new tab)
- Grant17 Feb 2022Publicly observed
NIH SBIR/STTR award: System for unitary automation of library preparation
USD 1,235,487.00 · National Institute of General Medical Sciences · Source: NIH RePORTER (opens in a new tab)
- Grant1 Sept 2021Publicly observed
NIH SBIR/STTR award: Rapid point-of-care molecular test for HCV VL
USD 996,914.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.